GW Pharmaceuticals PLC | Income Statement
Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
42,608.90
49,908.10
44,012.40
14,584.20
10,435.20
15,466.30
Cost of Goods Sold (COGS) incl. D&A
1,991.90
5,559.70
7,422.30
9,029.00
11,478.90
15,677.70
Gross Income
40,617.00
44,348.30
36,590.10
5,555.10
1,043.80
211.40
SG&A Expense
56,961.20
82,266.50
133,476.00
164,133.10
186,191.20
273,578.10
EBIT
16,344.20
37,918.20
96,885.90
158,578.00
187,235.00
273,789.50
Unusual Expense
-
-
934.50
-
530.80
-
Non Operating Income/Expense
-
5,295.60
9,564.30
36,126.10
6,390.60
2,126.40
Interest Expense
99.90
101.30
115.70
244.60
943.70
1,254.60
Pretax Income
16,166.20
32,507.90
87,995.50
121,836.90
193,053.00
268,273.20
Income Tax
9,065.00
8,157.70
19,273.50
31,833.50
26,242.40
4,059.80
Consolidated Net Income
7,101.20
24,350.20
68,721.90
90,003.40
166,810.60
272,333
Net Income
7,101.20
24,350.20
68,721.90
90,003.40
166,810.60
272,333
Net Income After Extraordinaries
7,101.20
24,350.20
68,721.90
90,003.40
166,810.60
272,333
Net Income Available to Common
7,101.20
24,350.20
68,721.90
90,003.40
166,810.60
272,333
EPS (Basic)
-
1.40
3.35
3.99
6.60
7.68
Basic Shares Outstanding
-
17,533.30
20,533.30
22,533.30
25,300.00
28,366.70
EPS (Diluted)
-
1.39
3.35
3.99
6.59
12
Diluted Shares Outstanding
-
17,533.30
20,533.30
22,533.30
25,300.00
28,366.70
EBITDA
14,800.30
35,595.90
93,335.90
153,393.30
180,241.50
264,422.40
Non-Operating Interest Income
277.90
215.90
376.30
859.60
2,047.00
8,897.30
About GW Pharmaceuticals
View Profile
